Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Suma Krishnan

Krystal Biotech, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Kriya Therapeutics develops gene therapies for conditions affecting millions of people globally, with a focus on making these therapies accessible. The company targets areas of high unmet need, utilizing innovative gene therapy approaches.

Kriya Therapeutics

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Metric
Company Name	Krystal Biotech, Inc.	Ardelyx, Inc.	Kriya Therapeutics
Symbol	KRYS	ARDX
MSH ID	COM:KRYSTALBIO	COM:ARDELYX	COM:KRIYATHERAPEUTICS
Market	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US
Stage		Debt	Series C
Employee Count	229	267
Website	krystalbio.com	ardelyx.com	kriyatherapeutics.com
LinkedIn
Founders

Metric
Market Cap	5.52B	1.30B
Enterprise Value
Monthly Web Traffic		33.50K	2.88K
Web Traffic Growth		2.80	-0.93
Valuation
Raised Capital		20M	150M

Metric
Revenue	50.70M	124.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit	42.60M	106.66M
EBITDA	-92.22M	-55.35M
Operating Income	-97.23M	-63.28M
Net Income	10.93M	-66.07M
EPS	0.40	-0.30
Diluted EPS	0.39	-0.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.96	0.86
Operating Profit Margin	-0.05	-0.28
EBITDA Margin	-1.82	-0.44
Net Profit Margin	0.64	-0.31
Return on Equity	0.13	-0.40
Return on Assets	0.12	-0.19
Return on Capital Employed	-0.01	-0.21

COM:KRYSTALBIO

Krystal Biotech, Inc.

Last Close

182.29

22/11 21:00

Market Cap

4.51B

Beta: -

Volume Today

222.08K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-105.15	-74.58
P/B Ratio	4.15	10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	94.13	14.47
EV Multiple	764.48	-20.25

Metric
Days Sales Outstanding	397.42	117.61
Days Payables Outstanding	7.10K	185.33
Days Inventory Outstanding	694.45	264.91
Operating Cycle	871.22	329.52
Cash Conversion Cycle	577.85	100.07
Asset Turnover	0.18	0.61

Metric
Operating Cash Flow	-88.80M	-89.72M
Free Cash Flow	-100.60M	-90.06M
Cash Flow to Debt	-2.18	-0.77
Operating Cash Flow/Sales	-0.08	-0.41
Free Cash Flow Yield	-0.04	-0.03

Metric
Cash & Equivalents	358.33M	21.47M
Accounts Receivable	-42.04M	-14.30M
Inventory	6.99M	12.45M
Goodwill
Debt to Capitalization	0.01	0.41
Debt to Assets	0.01	0.12
Current Ratio	21.10	5.54
Quick Ratio	17.35	4.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	4.63	0.09
R&D to Revenue	5.35	0.26
SG&A to Revenue	11.41	0.15